A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
Published date:
07/14/2015
Excerpt:
Patients who had clinical benefit had higher VEGF-C baseline values (P=0.04)....Sunitinib is well tolerated but only a select subgroup of patients benefited. Serum VEGF-A and -C may be early predictors of benefit.